TSHA
$2.45
Revenue | $3.6Mn |
Net Profits | $47.74Mn |
Net Profit Margins | 1324.67% |
Taysha Gene Therapies Inc’s revenue jumped 44.04% since last year same period to $3.6Mn in the Q4 2023. On a quarterly growth basis, Taysha Gene Therapies Inc has generated -24.06% fall in its revenue since last 3-months.
Taysha Gene Therapies Inc’s net profit jumped 182.23% since last year same period to $47.74Mn in the Q4 2023. On a quarterly growth basis, Taysha Gene Therapies Inc has generated 140.77% jump in its net profits since last 3-months.
Taysha Gene Therapies Inc’s net profit margin jumped 157.09% since last year same period to 1324.67% in the Q4 2023. On a quarterly growth basis, Taysha Gene Therapies Inc has generated 153.69% jump in its net profit margins since last 3-months.
EPS Estimate Current Quarter | -0.11 |
EPS Estimate Current Year | -0.11 |
Taysha Gene Therapies Inc’s earning per share (EPS) estimates for the current quarter stand at -0.11 - a 0% jump from last quarter’s estimates.
Taysha Gene Therapies Inc’s earning per share (EPS) estimates for the current year stand at -0.11.
Earning Per Share (EPS) | 0.92 |
Return on Assets (ROA) | -0.3 |
Return on Equity (ROE) | -2.94 |
Taysha Gene Therapies Inc’s earning per share (EPS) jumped 192.93% since last year same period to 0.92 in the Q4 2023. This indicates that the Taysha Gene Therapies Inc has generated 192.93% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Taysha Gene Therapies Inc’s return on assets (ROA) stands at -0.3.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Taysha Gene Therapies Inc’s return on equity (ROE) stands at -2.94.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2023-08-14 | -0.31 | -0.38 | -22.58% |
2024-03-19 | -0.11 | 0.92 | 936.36% |
2023-05-11 | -0.35 | -0.28 | 20% |
2023-11-14 | -0.17 | -0.13 | 23.53% |